Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Clinical Laboratory

Prognostic Value of Molecular and Clinical Features in Patients with NPM1 Gene Mutation in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaoyu LiKXKaiqiang Xi

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies flt3-ITD and dnmt3A mutations as adverse prognostic factors, suggesting enhanced treatment strategies.

Key Points

  • NPM1 mutations significantly influence outcomes in acute myeloid leukemia patients, indicating a need for tailored therapies.
  • Patients with FLT3-ITD mutations have a higher risk of recurrence, with HR of 2.55, prompting potential for more aggressive treatment.
  • Multivariate analysis pinpointed elevated WBC count and increased LDH levels as crucial adverse prognostic factors for recurrence-free survival.
  • Hematopoietic stem cell transplantation offers a protective effect regarding overall survival, presenting an important treatment avenue.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d413f8713b0b5dfea61c77https://doi.org/10.7754/clin.lab.2022.250132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic covariates associated with outcomes in patients with <i>NPM1</i>-mutated acute myeloid leukemia2025 · 3 citations
  2. 2Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  3. 3A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia2025 · 2 citations
  4. 4The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.2025
  5. 5DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study2025